Coherus BioSciences Inc
NASDAQ:CHRS

Watchlist Manager
Coherus BioSciences Inc Logo
Coherus BioSciences Inc
NASDAQ:CHRS
Watchlist
Price: 1.39 USD 2.96%
Market Cap: 168m USD

Intrinsic Value

The intrinsic value of one CHRS stock under the Base Case scenario is 2.03 USD. Compared to the current market price of 1.39 USD, Coherus BioSciences Inc is Undervalued by 32%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CHRS Intrinsic Value
2.03 USD
Undervaluation 32%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Coherus BioSciences Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about CHRS?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is CHRS valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Coherus BioSciences Inc.

Explain Valuation
Compare CHRS to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CHRS?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Coherus BioSciences Inc

Current Assets 461m
Cash & Short-Term Investments 191.7m
Receivables 250.5m
Other Current Assets 18.8m
Non-Current Assets 55.6m
PP&E 1.6m
Intangibles 49.5m
Other Non-Current Assets 4.4m
Current Liabilities 372.3m
Accounts Payable 24.9m
Accrued Liabilities 93.5m
Other Current Liabilities 253.9m
Non-Current Liabilities 56.4m
Long-Term Debt 50.6m
Other Non-Current Liabilities 5.9m
Efficiency

Free Cash Flow Analysis
Coherus BioSciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Coherus BioSciences Inc

Revenue
83.6m USD
Cost of Revenue
-43.6m USD
Gross Profit
39.9m USD
Operating Expenses
-210.7m USD
Operating Income
-170.8m USD
Other Expenses
325.8m USD
Net Income
155m USD
Fundamental Scores

CHRS Profitability Score
Profitability Due Diligence

Coherus BioSciences Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Exceptional Net Margin
Healthy Gross Margin
Strong 3Y Average Gross Margin
25/100
Profitability
Score

Coherus BioSciences Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

CHRS Solvency Score
Solvency Due Diligence

Coherus BioSciences Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
39/100
Solvency
Score

Coherus BioSciences Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CHRS Price Targets Summary
Coherus BioSciences Inc

Wall Street analysts forecast CHRS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CHRS is 5.1 USD with a low forecast of 4.04 USD and a high forecast of 6.3 USD.

Lowest
Price Target
4.04 USD
191% Upside
Average
Price Target
5.1 USD
267% Upside
Highest
Price Target
6.3 USD
353% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Coherus BioSciences Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CHRS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

CHRS Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one CHRS stock?

The intrinsic value of one CHRS stock under the Base Case scenario is 2.03 USD.

Is CHRS stock undervalued or overvalued?

Compared to the current market price of 1.39 USD, Coherus BioSciences Inc is Undervalued by 32%.

Back to Top